Adults with resected (R0) stage II or III esophageal or gastroesophageal junction cancer who had received neoadjuvant chemoradiotherapy and had residual pathological disease were randomly assigned ...

The primary outcome was overall survival (OS). This study is registered with EudraCT 2005-003318-13. Between March 15, 2006, and December 4, 2014, 447 patients were enrolled; 223 patients with BTC ...

Identification and validation of arsenic-associated genes and risk model for predicting lung cancer. This is an ASCO Meeting Abstract from the 2025 ASCO Annual Meeting I. This abstract does not ...

We undertook to determine whether adjuvant vinorelbine plus cisplatin prolongs overall survival among patients with completely resected early-stage non–small-cell lung cancer. A total of 482 ...

Overall survival data were still immature (HR 0.87; 95% CI 0.66 to 1.14). Through the Cancer Drugs Fund, systemic anti-cancer therapy data were collected from people having adjuvant nivolumab for ...

No novel therapeutic interventions have improved the clinical outcomes for patients with resected, recurrent osteosarcoma in over 40 years. The clinical updates reported today include: 1-year EFS ...

continue to show polyspecific T cell responses up to three years and delayed tumor recurrence in patients with resected pancreatic ductal adenocarcinoma (“PDAC”) A randomized Phase 2 clinical ...

Evidence-based recommendations on pembrolizumab (Keytruda) for the adjuvant treatment of resected stage 2B and 2C melanoma in people 12 years and over. Pembrolizumab is also recommended for the ...

Cryoablation during lobectomy for lung cancer appears to be a safe and cost-effective strategy for easing postoperative pain, according to a study published in Pain and Therapy. “Cryoablation is ...

OS Therapies Inc. (NYSE-A: OSTX) ("OS Therapies" or "the Company"), a clinical-stage cancer immunotherapy and antibody drug conjugate biotechnology company, today reported first quarter 2025 financial ...